AbbVie (NYSE: ABBV) Q4 CY2025: Revenue Surpasses Expectations

[Para 1] AbbVie (NYSE: ABBV) exceeded market revenue forecasts in Q4 CY2025, reporting a 10% year-over-year increase to $16.62 billion. Non-GAAP earnings per share were $2.71, surpassing analyst consensus by 2.2%. [Para 2-3] The pharmaceutical giant's strong performance is attributed to its diversified growth platform, particularly in new treatments and strategic pipeline investments. Despite facing a challenging year post-Humira exclusivity loss in 2023, AbbVie's revenue growth demonstrates resilience. Analysts predict 8.6% revenue growth over the next 12 months, indicating promising future prospects. Operating margins expanded to 27.3% in Q4, up significantly from the prior year, showcasing improved operational efficiency.